Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 20/20 | 0.51 |
| ▸ | MERTK | Q12866 | 20/20 | 0.51 |
| ▸ | GAS6 | Q14393 | 17/20 | 0.51 |
| ▸ | FLT3 | P36888 | 16/20 | 0.51 |
| ▸ | AXL | P30530 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052778 | 0.92 | HDAC1 (0.45) | TYRO3MERTKGAS6FLT3 | |
| SCHEMBL3050217 | 0.90 | HDAC1 (0.47) | TYRO3MERTKGAS6FLT3 | |
| SCHEMBL486036 | 0.88 | TYRO3 (0.51) | TYRO3MERTKGAS6FLT3AXL | |
| SCHEMBL3042675 | 0.88 | NAMPT (0.45) | TYRO3MERTKGAS6FLT3 | |
| SCHEMBL3055315 | 0.87 | FLT3 (0.56) | TYRO3MERTKGAS6FLT3 | |
| SCHEMBL3046675 | 0.86 | NAMPT (0.46) | TYRO3MERTKGAS6FLT3 | |
| SCHEMBL486043 | 0.85 | TYRO3 (0.47) | TYRO3MERTKGAS6FLT3AXL | |
| SCHEMBL3707122 | 0.82 | TYRO3 (0.45) | TYRO3MERTKGAS6FLT3AXL | |
| SCHEMBL3054524 | 0.81 | HDAC1 (0.46) | — | |
| SCHEMBL3057949 | 0.80 | HDAC1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| EP-2205566-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | TYRO3 2797/4885MERTK 2529/4885GAS6 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.